Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

Autor: Khunti, Kamlesh, Kosiborod, Mikhail, Kim, Dae Jung, Kohsaka, Shun, Lam, Carolyn S.P., Goh, Su Yen, Chiang, Chern En, Shaw, Jonathan, Cavender, Matthew A., Tangri, Navdeep, Franch-Nadal, Josep, Holl, Reinhard W., Jørgensen, Marit Eika, Norhammar, Anna, Eriksson, Johan G., Zaccardi, Francesco, Karasik, Avraham, Magliano, Dianna J., Thuresson, Marcus, Chen, Hungta, Wittbrodt, Eric, Bodegård, Johan, Surmont, Filip, Fenici, Peter, Wilding, John P., Carstensen, Bendix, Kendrick, Rachel, Belli, Wesley, Wittbrodt, Eric T., Noguchi, Yusuke, Andersson-Sundell, Karolina
Přispěvatelé: Clinicum, Research Programs Unit, Johan Eriksson / Principal Investigator, Department of General Practice and Primary Health Care, HUS Helsinki and Uusimaa Hospital District, University of Manitoba, Cardiovascular Centre (CVC)
Rok vydání: 2021
Předmět:
Blood Glucose
Male
Time Factors
Endocrinology
Diabetes and Metabolism
Sodium–glucose cotransporter-2 inhibitors
Type 2 diabetes
030204 cardiovascular system & hematology
THERAPIES
INITIATION
0302 clinical medicine
Risk Factors
Sodium-glucose cotransporter-2 inhibitors
Medicine
Myocardial infarction
Stroke
Cardiovascular Diseases/diagnosis
Original Investigation
RISK
ASIA
Hazard ratio
DEATH
Middle Aged
3. Good health
Hospitalization
Treatment Outcome
TRIALS
Cardiovascular Diseases
Female
Diabetes Mellitus
Type 2/blood
Cardiology and Cardiovascular Medicine
Cardiovascular outcomes
medicine.medical_specialty
Heart failure
030209 endocrinology & metabolism
Glycemic Control
Lower risk
Risk Assessment
03 medical and health sciences
Blood Glucose/drug effects
Diabetes mellitus
Internal medicine
Diseases of the circulatory (Cardiovascular) system
Humans
Sodium-Glucose Transporter 2 Inhibitors
Aged
business.industry
Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MORTALITY
Protective Factors
medicine.disease
Clinical trial
Diabetes Mellitus
Type 2
RC666-701
3121 General medicine
internal medicine and other clinical medicine
Propensity score matching
business
Zdroj: Khunti, K, Kosiborod, M, Kim, D J, Kohsaka, S, Lam, C S P, Goh, S Y, Chiang, C E, Shaw, J, Cavender, M A, Tangri, N, Franch-Nadal, J, Holl, R W, Jørgensen, M E, Norhammar, A, Eriksson, J G, Zaccardi, F, Karasik, A, Magliano, D J, Thuresson, M, Chen, H, Wittbrodt, E, Bodegård, J, Surmont, F, Fenici, P, Kosiborod, M, Cavender, M A, Wilding, J P, Khunti, K, Norhammar, A, Carstensen, B, Holl, R W, Lam, C S P, Kendrick, R, Belli, W, Wittbrodt, E T, Franch-Nadal, J, Noguchi, Y, Karasik, A, Tangri, N, Kohsaka, S, Kim, D J, Shaw, J, Andersson-Sundell, K, Goh, S Y, Chiang, C E, Eriksson, J G, Zaccardi, F, Fenici, P, Bodegård, J & on behalf of the CVD-REAL Investigators and Study Group 2021, ' Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents : analysis of CVD-REAL data ', Cardiovascular Diabetology, vol. 20, no. 1, 159 . https://doi.org/10.1186/s12933-021-01345-z
Cardiovascular Diabetology, 20(1):159. BioMed Central Ltd.
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)
Cardiovascular Diabetology
CARDIOVASCULAR DIABETOLOGY
ISSN: 1475-2840
DOI: 10.1186/s12933-021-01345-z
Popis: Background Randomized, controlled cardiovascular outcome trials may not be fully representative of the management of patients with type 2 diabetes across different geographic regions. We conducted analyses of data from the multinational CVD-REAL consortium to determine the association between initiation of sodium–glucose cotransporter-2 inhibitors (SGLT-2i) and cardiovascular outcomes, including subgroup analyses based on patient characteristics. Methods De-identified health records from 13 countries across three continents were used to identify patients newly-initiated on SGLT-2i or other glucose-lowering drugs (oGLDs). Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching for oGLD initiation. In the matched groups hazard ratios (HRs) for hospitalization for heart failure (HHF), all-cause death (ACD), the composite of HHF or ACD, myocardial infarction (MI) and stroke were estimated by country, and pooled using a weighted meta-analysis. Multiple subgroup analyses were conducted across patient demographic and clinical characteristics to examine any heterogeneity in treatment effects. Results Following matching, 440,599 new users of SGLT-2i and oGLDs were included in each group. Mean follow-up time was 396 days for SGLT-2i initiation and 406 days for oGLDs initiation. SGLT-2i initiation was associated with a lower risk of HHF (HR: 0.66, 95%CI 0.58–0.75; p Conclusions This CVD-REAL study extends the findings from the SGLT-2i clinical trials to the broader setting of an ethnically and geographically diverse population, and across multiple subgroups. Trial registration NCT02993614
Databáze: OpenAIRE
Externí odkaz: